MS Treatments Episodes

Our coverage of MSToronto 2026 continues this week with two important conversations. First, we'll hear from Dr. Jeffrey Cohen about the latest clinical findings on CAR-T cell therapy as a potential treatment for MS. Then, Dr. Robert Fox will update us on the global research portfolio being driven by the International Progressive MS Alliance. And we have to talk about Christina Applegate. By now, the news of her misdiagnosis isn't really news. But we have some suggestions...

Jan Janisch-Hanzlik was the first MS patient to receive CAR T-cell therapy as part of a clinical trial. We met Jan last year, in episode 424 of RealTalk MS, when she gave us a first-hand report on how she was responding to this treatment. This week, Jan is back with an update on how she's responding to CAR T-cell therapy one year later. We're just two weeks away from the U.S. midterm elections. We're sharing some resources that will help you get ready to v...

Relapses make life with MS unpredictable. Understanding what they are, why they happen, and how best to manage them can make a relapse less scary and easier to navigate. This week, Dr. Gabriela Karolidis, a board-certified neurologist and neuroimmunologist at Thomas Jefferson University, joins us for a deep dive into MS relapses. The MS International Federation has just updated the Atlas of MS, showing more than 3 million people living with MS worldwide. We're sharing the det...

Imagine your spouse or significant other has been diagnosed with MS...shortly after you were diagnosed with stage IV colon cancer, and given just a 15% chance of survival. All of a sudden, the roles of patient and care partner are up for grabs -- and they change with almost daily frequency. That's exactly the scenario my guest, Kathleen Silva, faced. Kathleen is joining me to discuss how she and her husband, Rick, survived and thrived amid that frightening chaos. (Spoiler alert -- no one died!)...

If you Google the term "shared decision making", you'll find it defined as a collaborative process where patients and clinicians work together to select tests, treatments, and care plans based on clinical evidence and the patient's personal values and goals. But shared decision-making isn't an automatic happy pill. It takes work, it takes discipline, and it takes a clear understanding of both the patient's and the clinician's roles. This week, Dr. Aliza Ben-Zacharia and Linda Lachman join me to...

We get more listener emails about diet and MS than almost any other topic. If you're curious about how some of the well-known diets for MS actually stack up, or you're interested in understanding the connection between diet and MS-related fatigue, or you want to know what the biggest obstacle to staying on a new diet is (and this may surprise you), then this is the episode for you. We're devoting this week's entire episode to my conversation with Dr. Tyler Titcomb, an assistant professor in the...

During his fellowship in the United States, Dr. Avinash Chandra trained to become an MS specialist at a world-class MS center. Then he returned home to Nepal and discovered that MS was largely considered non-existent. But Dr. Chandra knew it wasn't. In this week's episode, Dr. Chandra discusses his experience creating a framework for MS care in Nepal that hadn't existed before. He also explains the necessary trade-offs in providing costly medical treatment in a country where the average family ...

Living with depression has been described as "like living under a wet, heavy blanket". It can stop someone from showing up at work, meeting up with friends, and even connecting with their family. One out of every two people living with MS will experience depression at some point in their MS journey. The METS for MS study is focused on a novel approach to treating major depressive disorder among people with MS -- one that doesn't require another infusion, injection, or pill. This week, Dr. ...

A short while ago, we shared very positive results from the Phase 3 clinical trials for fenebrutinib in both relapsing-remitting and primary progressive MS. Those results have been submitted to the FDA for approval. This week, Dr. Jiwon Oh, the principal investigator in one of the Phase 3 trials for fenebrutinib, walks us through these positive results and explains what makes fenebrutinib a different kind of disease-modifying therapy and who might benefit most from it. We're also talking about...

For years, the standard medical advice for someone diagnosed with multiple sclerosis was simple, cautious, and as we now know, incredibly limiting: "Take it easy. Don't overexert yourself. And get plenty of rest." Today, like almost every other aspect of MS care, neurological rehabilitation is being entirely rewritten. It's no longer about just managing decline; it's about leveraging emerging technologies to proactively build resilience, retrain the brain, and adopt cutting-edge exercise science...